We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation.
- Authors
Laskin, Benjamin L; Denburg, Michelle R; Furth, Susan L; Moatz, Taylor; Altrich, Michelle; Kleiboeker, Steve; Lutzko, Carolyn; Zhu, Xiang; Blackard, Jason T; Jodele, Sonata; Lane, Adam; Wallace, Gregory; Dandoy, Christopher E; Lake, Kelly; Duell, Alexandra; Litts, Bridget; Seif, Alix E; Olson, Timothy; Bunin, Nancy; Davies, Stella M
- Abstract
Background BK polyomavirus (BKPyV) is associated with symptomatic hemorrhagic cystitis after hematopoietic cell transplantation (HCT). Little is known about the host immune response, effectiveness of antiviral treatment, or impact of asymptomatic replication on long-term kidney function. Methods In children and young adults undergoing allogeneic HCT, we quantified BKPyV viruria and viremia (pre-HCT and at Months 1–4, 8, 12, and 24 post-HCT) and tested associations of peak viremia ≥10 000 or viruria ≥109 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and overall survival at 2 years posttransplant. We examined the factors associated with viral clearance by Month 4, including BKPyV-specific T cells by enzyme-linked immune absorbent spot at Month 3 and cidofovir use. Results We prospectively enrolled 193 participants (median age 10 years) and found that 18% had viremia ≥10 000 copies/mL and 45% had viruria ≥109 copies/mL in the first 3 months post-HCT. Among the 147 participants without cystitis (asymptomatic), 58 (40%) had any viremia. In the entire cohort and asymptomatic subset, having viremia ≥10 000 copies/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT. Viremia ≥10 000 copies/mL was associated with a higher risk of death (adjusted hazard ratio, 2.2; 95% confidence interval, 1.1–4.2). Clearing viremia was associated with detectable BKPyV-specific T cells and having viremia <10 000 copies/mL, but not cidofovir exposure. Conclusions Screening for BKPyV viremia after HCT identifies asymptomatic patients at risk for kidney disease and reduced survival. These data suggest potential changes to clinical practice, including prospective monitoring for BKPyV viremia to test virus-specific T cells to prevent or treat BKPyV replication.
- Subjects
ANTIVIRAL agents; CONFIDENCE intervals; CREATININE; ENZYME-linked immunosorbent assay; GLOMERULAR filtration rate; HEMATOPOIETIC stem cell transplantation; LONGITUDINAL method; SURVIVAL analysis (Biometry); T cells; POLYOMAVIRUS diseases; VIREMIA
- Publication
Clinical Infectious Diseases, 2020, Vol 71, Issue 12, p3044
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciz1194